Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII,X and XI)
Dr. Hargrave et al., Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII,X and XI), BR J HAEM, 112(2), 2001, pp. 293-299
In the last 20 years, the survival rate for children with acute lymphoblast
ic leukaemia (ALL) has markedly improved, largely owing to a decrease in re
lapses. However, children still die from complications of treatment and the
se are potentially preventable. We have analysed data from three large cons
ecutive national protocols for ALL from 1980 to 1997 [Medical Research Coun
cil United Kingdom ALL (MRC UKALL) trials VIII, X and XI] to compare the in
cidence and causes of treatment-related deaths (TRD). The percentage of TRD
has fallen from 9% to 2% (UKALL VIII to XI), largely as a result of a decr
ease in fatal infections. Deaths during induction have fallen from 3% to 1%
, the main causes of death being bacterial, followed by fungal infection, w
hile other causes, chiefly haemorrhage, have not declined. Remission deaths
also decreased from 6% to 1%, particularly those deaths due to measles and
pneumocystis carinii. More guidelines for surveillance and treatment of in
fections have been included within progressively more intensive protocols.
Risk factor analysis showed increased TRD in patients with Down's syndrome,
high leucocyte count and older age in UKALL XI. In contrast, the introduct
ion of blocks of intensification was not associated with an increased death
rate. While improved supportive care has reduced the incidence of TRD, the
re is still scope for further reduction by prompt treatment of suspected in
fection. Maintenance of herd immunity remains of vital importance in avoidi
ng deaths from measles.